Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Supreme Court Copaxone Case May Weaken Federal Circuit Review Of Patent Claims

This article was originally published in The Pink Sheet Daily

Executive Summary

Teva has a chance to block generic competition until Sept. 1, 2015; high court declines to hear False Claims Act case against Takeda and a challenge to Allergan’s Combigan patent.

You may also be interested in...

Teva Appeals In Delhi High Court To Block Natco’s Export Of Glatiramer

Teva’s petition to stop Natco from exporting glatiramer was dismissed by the Delhi High in February. The company has now appealed to a double bench in its continued efforts to prove that Natco’s move to export the compound infringes its international patents.

Takeda False Claim Act Case May Allow Supreme Court To Set Evidence Threshold

High court seeks Solicitor General’s views on whether a whistleblower must identify a specific false claim submitted to the government or just have evidence to infer the submission; Solicitor General has previously supported latter position.

Teva’s Final Copaxone Firewall Is Complexity Of ANDA Review After Court Tosses Patent

Federal Circuit finds claims covering Copaxone’s latest expiring patent are invalid; Mylan says it plans to launch its generic of the MS drug in May 2014.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts